Thrombomodulin regulates doxorubicin sensitivity through epithelial-mesenchymal transition in non-small cell lung cancer.
CONCLUSIONS: These findings showed that TM regulated drug sensitivity through EMT in lung cancer cells, suggesting that TM might be developed into a novel target for lung cancer patients resistant to conventional therapeutics.
PMID: 28121350 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Epithelial Cancer | Lung Cancer | Non-Small Cell Lung Cancer